Final results for VV116 (mindeudesivir hydrobromide) shows efficacy in COVID 19 trial – Junishi Biosciences
Junshi Biosciences has revealed the final results for its Covid-19 pill VV 116 (mindeudesivir hydrobromide), indicating its efficacy. The data, which was published in The Lancet Infectious Diseases… read more.